Prof Stephen Gillespie

Prof Stephen Gillespie
Sir James Black Chair of Medicine



data source: symbiosis

Research Overview from research@st-andrews

Stephen Gillespie has worked in Kenya researching the relationship between malaria and lower respiratory tract infection and the prevalence of parasitic infection in children in Kilifi, Kenya. He has investigated a cholera epidemic and vaccine failures in Guerrero, Mexico. He has been working in collaboration with colleagues at Kilimanjaro Christian Medical Centre since 1988 where he has, variously, studied respiratory and parasite diagnostics and novel antimalarials, anti-helminthics and anti tuberculosis agents. His main research activity is in the area of tuberculosis drug development.

For the last twenty five years Stephen Gillespie has been involved in various aspects of  tuberculosis diagnosis and drug development. This has included the evaluation of new candidate antituberculosis agents in vitro. This work has expanded into studies of the molecular mechanisms of resistance and the development of model systems to measure the fitness deficits found in resistant strains. He has been involved in the development of fluoroquinolones for tuberculosis having performed early bacterial activity studies and clinical trials of ciprofloxacin. More recently he has led the group working on the clinical development of moxifloxacin in collaboration with the Global Alliance for TB Drug Development as Chief Investigator of the REMox TB study. He later went on to be the coordinating investigator for the TB Alliance STAND trial (Shortening Treatment by Advancing New Drugs). He is also one of the Chief Investigators of the PanACEA consortium that links European and African research groups in enhancing anti-tuberculosis therapy.  

He has an extensive record of developing novel mirobiological diagnostics.  Most recently, he has developed SLIC (Scattered Light Integrating Collector),  which performs phenotypic antibiotic susceptibility testing in less than 30 minutes. This innovation recently won a Longitude Prize Discovery Award. In addition he has developed the Molecular Bacterial Load Assay, an innovative way of detecting, quantifiying and determining the viability of bacteria in a single test that allows both diagnosis and the monitoring of treatment response.


source: research@st-andrews
Recent publications listed in research@st-andrews
Tweed, CD, Crook, AM, Amukoye, EI, Dawson, R, Diacon, AH, Hanekom, M, McHugh, TD, Mendel, CM, Meredith, SK, Murphy, ME, Murthy, SE, Nunn, AJ, Phillips, PPJ, Singh, KP, Spigelman, M, Wills, GH & Gillespie, SH 2018, 'Toxicity associated with tuberculosis chemotherapy in the REMoxTB study' BMC Infectious Diseases, vol 18, 317. DOI: 10.1186/s12879-018-3230-6
Svensson, EM, Svensson, RJ, Te Brake, LHM, Boeree, MJ, Heinrich, N, Konsten, S, Churchyard, G, Dawson, R, Diacon, AH, Kibiki, GS, Minja, LT, Ntingiya, NE, Sanne, I, Gillespie, SH, Hoelscher, M, Phillips, PPJ, Simonsson, USH & Aarnoutse, R 2018, 'The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis' Clinical Infectious Diseases, vol 67, no. 1, pp. 34-41. DOI: 10.1093/cid/ciy026
Murthy, SE, Chatterjee, F, Crook, A, Dawson, R, Mendel, C, Murphy, ME, Murray, SR, Nunn, AJ, Phillips, PPJ, Singh, KP, McHugh, TD, Gillespie, SH & on behalf of the REMoxTB Consortium 2018, 'Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis' BMC Medicine, vol 16, 73. DOI: 10.1186/s12916-018-1053-3
Svensson, RJ, Svensson, EM, Aarnoutse, RE, Diacon, AH, Dawson, R, Gillespie, SH, Moodley, M, Boeree, MJ & Simonsson, USH 2018, 'Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations' Journal of Infectious Diseases, vol In press. DOI: 10.1093/infdis/jiy242
Rachow, A, Saathoff, E, Mtafya, B, Mapamba, D, Mangu, C, Rojas-Ponce, G, Ntinginya, NE, Boeree, M, Heinrich, N, Gillespie, SH, Hoelscher, M & on behalf of the PanACEA-Consortium 2018, 'The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay' Tuberculosis, vol In press. DOI: 10.1016/j.tube.2018.04.001
Fregonese, F, Ahuja, SD, Akkerman, OW, Arakaki-Sanchez, D, Ayakaka, I, Baghaei, P, Bang, D, Bastos, M, Benedetti, A, Bonnet, M, Cattamanchi, A, Cegielski, P, Chien, J-Y, Cox, H, Dedicoat, M, Erkens, C, Escalante, P, Falzon, D, Garcia-Prats, AJ, Gegia, M, Gillespie, SH, Glynn, JR, Goldberg, S, Griffith, D, Jacobson, KR, Johnston, JC, Jones-López, EC, Khan, A, Koh, W-J, Kritski, A, Lan, ZY, Lee, JH, Li, PZ, Maciel, EL, Galliez, RM, Merle, CSC, Munang, M, Narendran, G, Nguyen, VN, Nunn, A, Ohkado, A, Park, JS, Phillips, PPJ, Ponnuraja, C, Reves, R, Romanowski, K, Seung, K, Schaaf, HS, Skrahina, A, Soolingen, DV, Tabarsi, P, Trajman, A, Trieu, L, Banurekha, VV, Viiklepp, P, Wang, J-Y, Yoshiyama, T & Menzies, D 2018, 'Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis' The Lancet Respiratory Medicine, vol 6, no. 4, pp. 265-275. DOI: 10.1016/S2213-2600(18)30078-X
Tweed, CD, Wills, GH, Crook, AM, Dawson, R, Diacon, AH, Louw, CE, McHugh, TD, Mendel, C, Meredith, S, Mohapi, L, Murphy, ME, Murray, S, Murthy, S, Nunn, AJ, Phillips, PPJ, Singh, K, Spigelman, M & Gillespie, SH 2018, 'Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study' BMC Medicine, vol 16, 46. DOI: 10.1186/s12916-018-1033-7
Baron, VO, Chen, M, Clark, SO, Williams, A, Dholakia, K & Gillespie, SH 2018, Detecting phenotypically resistant Mycobacterium tuberculosis using wavelength modulated Raman spectroscopy. in S Gillespie (ed.), Antibiotic Resistance Protocols. Methods in Molecular Biology, vol. 1736, Humana Press/Springer, New York, NY, pp. 41-50. DOI: 10.1007/978-1-4939-7638-6_4
Hammond, RJH, Baron, VO, Lipworth, S & Gillespie, SH 2018, Enhanced methodologies for detecting phenotypic resistance in mycobacteria. in S Gillespie (ed.), Antibiotic Resistance Protocols. Methods in Molecular Biology, vol. 1736, Humana Press/Springer, New York, NY, pp. 85-94. DOI: 10.1007/978-1-4939-7638-6_8
Xaio, H & Gillespie, SH 2018, Using RT qPCR for quantifying Mycobacteria marinum from in vitro and in vivo samples. in S Gillespie (ed.), Antibiotic Resistance Protocols. Methods in Molecular Biology, vol. 1736, Humana Press/Springer, New York, NY, pp. 137-145. DOI: 10.1007/978-1-4939-7638-6_13
Aarnoutse, RE, Kibiki, GS, Reither, K, Semvua, HH, Haraka, F, Mtabho, CM, Mpagama, SG, van den Boogaard, J, Sumari-de Boer, IM, Magis-Escurra, C, Wattenberg, M, Logger, JGM, te Brake, LHM, Hoelscher, M, Gillespie, SH, Colbers, A, Phillips, PPJ, Plemper van Balen, G, Boeree, MJ & PanACEA Consortium 2017, 'Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis' Antimicrobial Agents and Chemotherapy, vol 61, no. 11, e01054-17. DOI: 10.1128/AAC.01054-17
Murphy, ME, Phillips, PPJ, Mendel, CM, Bongard, E, Bateson, ALC, Hunt, R, Murthy, S, Singh, KP, Brown, M, Crook, AM, Nunn, AJ, Meredith, SK, Lipman, M, McHugh, TD, Gillespie, SH & on behalf of the REMoxTB Consortium 2017, 'Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis' BMC Medicine, vol 15, 192. DOI: 10.1186/s12916-017-0947-9
Muliaditan, M, Davies, GR, Simonsson, USH, Gillespie, SH & Pasqua, OD 2017, 'The implications of model–informed drug discovery and development for tuberculosis' Drug Discovery Today, vol 22, no. 3, pp. 481-486. DOI: 10.1016/j.drudis.2016.09.004